Comparative study of breast cancer with or without concomitant Paget disease: An analysis of the SEER database

Shijing Chen, Huaquan Chen, Ying Yi, Xuemei Jiang, Hai Lei, Xue Luo, Yu Chen, Sha Liu, Dan Yuan, Xinjian Jia, Junyan Li, Shijing Chen, Huaquan Chen, Ying Yi, Xuemei Jiang, Hai Lei, Xue Luo, Yu Chen, Sha Liu, Dan Yuan, Xinjian Jia, Junyan Li

Abstract

Background: Most mammary Paget disease (MPD) is associated with underlying in situ or invasive breast cancer. The objective of this study was to compare the clinicopathological characteristics and survival outcomes between breast cancer with Paget disease (PD) and breast cancer alone.

Methods: From the Surveillance, Epidemiology, and End Results (SEER) database, 2000-2015, of the US National Cancer Institute, we identified 1569 women who had PD with invasive ductal carcinoma (PD-IDC) and 1489 women who had PD with ductal carcinoma in situ (PD-DCIS). Independent demographic and clinicopathological variables as well as survival outcomes of these patients were compared to patients with the corresponding breast cancer without concomitant PD.

Results: PD-IDC and PD-DCIS both had worse survival outcomes and poorer tumor characteristics than the corresponding disease without PD. Contrary to in the breast cancer alone groups, in the breast cancer with PD groups, the HR status (P = 0.182 in PD-IDC and P = 0.371 in PD-DCIS), HER2 status (P = 0.788 in PD-IDC and P = 0.643 in PD-DCIS), and combined molecular subtype (P = 0.196 in PD-IDC and P = 0.853 in PD-DCIS) were not found to affect disease prognosis. After matching tumor characteristics and treatment approaches, PD-IDC as well as PD-DCIS exhibited no significant difference in disease prognosis with corresponding IDC and DCIS. Finally, by comparative analysis, a kind of PD-DCIS (ICD-O-3 code 8543/3) showed many invasive behaviors (31.8% of 8543/3 patients had stage I-III cancer) and was associated with worse survival outcomes than the other type of PD-DCIS.

Conclusions: Breast cancer with concomitant PD was associated with more aggressive tumor characteristics and worse survival outcomes. The HR status, HER2 status, and combined molecular subtype could not affect the prognosis of breast cancer with PD. Moreover, a portion of the PD-DCIS cases were invasive breast cancer cases that required special treatment.

Keywords: Breast Cancer; Ductal Carcinoma In Situ; Epidemiology; Infiltrating Ductal Carcinoma; Mammary Paget Disease; Surveillance; and End Results.

Conflict of interest statement

All authors declare that they have no conflict of interest.

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Kaplan‐Meier curves without adjusting for tumor characteristics and treatment approaches. (A) Overall survival of the PD‐IDC group and the IDC group. (B) Disease‐specific survival of the PD‐IDC group and IDC group. (C) Overall survival of the PD‐DCIS group and the DCIS group. (D) Disease‐specific survival of the PD‐DCIS group and the DCIS group
Figure 2
Figure 2
Kaplan‐Meier curves after matched for tumor characteristics and treatment. (A) overall survival of PD‐IDC group and IDC group. (B) disease‐specific survival of PD‐IDC group and IDC group. (C) overall survival of PD‐DCIS group and DCIS group. (D) disease‐specific survival of PD‐DCIS group and DCIS group

References

    1. Lopes Filho LL, Lopes I, Lopes L, Enokihara M, Michalany AO, Matsunaga N. Mammary and extramammary Paget's disease. An Bras Dermatol. 2015;90:225‐231.
    1. Caliskan M, Gatti G, Sosnovskikh I, et al. Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2008;112:513‐521.
    1. Paone JF, Baker RR. Pathogenesis and treatment of Paget's disease of the breast. Cancer. 1981;48:825‐829.
    1. Sandoval‐Leon AC, Drews‐Elger K, Gomez‐Fernandez CR, Yepes MM, Lippman ME. Paget's disease of the nipple. Breast Cancer Res Treat. 2013;141:1‐12.
    1. Chen CY, Sun LM, Anderson BO. Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer. 2006;107:1448‐1458.
    1. Sek P, Zawrocki A, Biernat W, Piekarski JH. HER2 molecular subtype is a dominant subtype of mammary Paget's cells. An immunohistochemical study. Histopathology. 2010;57:564‐571.
    1. Zhao Y, Sun H‐F, Chen M‐T, et al. Clinicopathological characteristics and survival outcomes in Paget disease: a SEER population‐based study. Cancer Med. 2018;7:2307‐2318.
    1. Ling H, Hu X, Xu X‐L, Liu Z‐B, Shao Z‐M. Patients with nipple‐areola Paget's disease and underlying invasive breast carcinoma have very poor survival: a matched cohort study. PLoS ONE. 2013;8:e61455.
    1. Zhou H, Lu K, Zheng L, et al. Prognostic significance of mammary Paget’s disease in Chinese women: a 10 year, population‐based, matched cohort study. OncoTargets and Therapy. 2018;11:8319‐8326.
    1. Wong SM, Freedman RA, Sagara Y, et al. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer. 2015;121:4333‐4340.
    1. Durkan B, Bresee C, Bose S, Phillips EH, Dang CM. Paget's disease of the nipple with parenchymal ductal carcinoma in situ is associated with worse prognosis than Paget's disease alone. Am Surg. 2013;79:1009‐1012.
    1. Lim HS, Jeong SJ, Lee JS, et al. Paget disease of the breast: mammographic, US, and MR imaging findings with pathologic correlation. Radiographics. 2011;31:1973‐1987.
    1. Lee H‐W, Kim TE, Cho SY, et al. Invasive Paget disease of the breast: 20 years of experience at a single institution. Hum Pathol. 2014;45:2480‐2487.
    1. NCCN Clinical Practice Guidelines in Oncology . NCCN Guidelines®. NCCN. Breast Cancer Web site. 2018. . Accessed October 25, 2018.
    1. Wachter DL, Wachter PW, Fasching PA, et al. Characterization of molecular subtypes of paget disease of the breast using immunohistochemistry and in situ hybridization. Arch Pathol Lab Med. 2019;143(2):206‐211.
    1. Zhou S, Zhong W, Mai R, Zhang G. Mammary and extramammary paget's disease presented different expression pattern of steroid hormone receptors. Biomed Res Int. 2017;2017:3768247.
    1. Sek P, Zawrocki A, Biernat W, Piekarski JH. HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemical study. Histopathology. 2010;57(4):564‐571.
    1. Zhou S, Zhong W, Mai R, Zhang G. Mammary and extramammary Paget’s disease presented different expression pattern of steroid hormone receptors. Biomed Res Int. 2017;2017:1‐5.
    1. Liegl B, Horn LC, Moinfar F. Androgen receptors are frequently expressed in mammary and extramammary Paget’s disease. Mod Pathol. 2005;18:1283‐1288.
    1. Yoneyama K, Kamada N, Kinoshita K, et al. Androgen‐deprivation regimen for multiple bone metastases of extramammary Paget disease. Br J Dermatol. 2005;153:853‐855.
    1. Siponen E, Hukkinen K, Heikkila P, Joensuu H, Leidenius M. Surgical treatment in Paget's disease of the breast. Am J Surg. 2010;200:241‐246.
    1. Wu QI, Ding X, Li J, et al. Surgical treatment in Paget's disease with invasive ductal carcinoma: an observational study based on SEER. Sci Rep. 2017;7:45510.
    1. Kawase K, DiMaio DJ, Tucker SL, et al. Paget's disease of the breast: there is a role for breast‐conserving therapy. Ann Surg Oncol. 2005;12:391‐397.
    1. Laronga C, Hasson D, Hoover S, et al. Paget's disease in the era of sentinel lymph node biopsy. Am J Surg. 2006;192:481‐483.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner